Interestingly, recent studies have shown that the administration of TLR2, TLR4 and TLR9 antagonists may have positive effects in AD and MS (Gambuzza et al., 2014; Gooshe et al., 2014). The gene discussed is TLR2; the disease is myeloid sarcoma.